elise.lammertyn@cf-europe.eu

Kaftrio also for people without an F508del mutation?

Kaftrio also for people without an F508del mutation?

In November, Vertex submitted an application to the European Medicines Agency EMA to extend the use of Kaftrio to people with specific mutations beyond F508del, aged 2 years and older. Until now, Kaftrio had only been approved and reimbursed for people with at least one F508del mutation, but this extension would also make people with […]